Approved Risk Evaluation and Mitigation Strategies (REMS)

Contact Us | REMS Basics | Gov Delivery Get REMS Email Alerts | Reports & Data Files

Blincyto (blinatumomab)
BLA #125557
REMS last update: 07/12/2017



What is the purpose of the REMS?

The goals of the BLINCYTO REMS are to mitigate the risk of cytokine release syndrome which may be life-threatening or fatal; the risk of neurological toxicities which may be severe, life-threatening, or fatal; and the risk of preparation and administration errors associated with use of BLINCYTO by:

  1. Informing healthcare providers about the risk of cytokine release syndrome which may be life-threatening or fatal
  2. Informing healthcare providers about the risk of neurological toxicities which may be severe, life-threatening, or fatal
  3. Informing pharmacists, who will prepare and dispense BLINCYTO, and nurses, who will administer BLINCYTO, about the risk of preparation and administration errors associated with use of BLINCYTO

What do participants need to know?

Healthcare providers should read the relevant Medication Guide or communication materials included in the product-specific approved REMS to learn about the risk(s). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website See Disclaimer page regarding links to external sites

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Blincyto REMS, see the DailyMed link(s).
Material Name Material Name Link
Fact Sheet for Providers (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Fact_Sheet_for_Providers.pdf
REMS document (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Document.pdf
REMS full (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_Full.pdf
REMS Letter for Healthcare Providers (email and print versions) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Letter_for_Healthcare_Providers_email_and_print_versions.pdf
REMS Letter for Hospital and Home Healthcare Pharmacists (email and print versions) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Letter_for_Hospital_and_Home_Healthcare_Pharmacists_email_and_print_versions.pdf
REMS Letter for Professional Societies (email and print versions) (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Letter_for_Professional_Societies_email_and_print_versions.pdf
REMS Website Screenshot (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/rems/Blincyto_2017-07-12_REMS_Website_Screenshot.pdf

What updates have been made to the REMS?

Date Summary of change
07/12/2017 Modified to incorporate the proposed changes to the Prescribing Information and make other minor edits to the REMS materials.
01/30/2017 Revised to make an editorial change(s).
08/30/2016 Modified to include the distribution of the REMS Letter for Professional Societies to pediatric-related professional societies and organizations in the communication plan.
12/03/2014 Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English